Project Grant HT94252310856
Award Date
9/30/23
Completion Date
9/29/26
Dollars Obligated
$536K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
This $3,945,543 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports cancer research and care initiatives at the University of Texas MD Anderson Cancer Center (MD Anderson). The award will fund a 4-year clinical research extension project to advance progress, precision, and equity in breast cancer care. MD Anderson, a leading comprehensive cancer center, will utilize the funding to conduct research activities that...
The federal Project Grant award of $728,043 was granted by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program to The University of Texas M.D. Anderson Cancer Center in Houston, TX. The funding will support research to delineate the tumor ecology and genomic progression of lobular breast cancers over a period of 3 years from February 2025 to January 2028. This research aims to transform healthcare for military service members, veterans, and the...
This Project Grant award, totaling $486,000.00, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award supports research conducted by the University of Texas MD Anderson Cancer Center, a component of the University of Texas System, to target PRMT5 in MTAP-loss melanoma. The project aims to transform health care for Service Members and the public through innovative and impactful cancer research, with a focus on...
This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $1,444,922.00 to the University of Texas MD Anderson Cancer Center (MD Anderson) to conduct research on a novel epigenetic determinant in metastatic prostate cancer. The award period is from September 15, 2024 to September 14, 2027. MD Anderson, a comprehensive cancer research and treatment center, will utilize this funding to carry out basic,...
The University of Texas MD Anderson Cancer Center received a $647,998 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award will fund research to develop image-guided, bidirectional EphB4 agonist-based therapy for ovarian cancer over a 4-year period from September 1, 2023 to August 31, 2027. MD Anderson, a comprehensive cancer treatment and research center, has extensive experience conducting basic,...
The University of Texas MD Anderson Cancer Center received a $647,990 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). This three-year grant, effective June 1, 2024, supports research to investigate cell plasticity and epigenetic reprogramming mechanisms underlying the transition of well-differentiated to de-differentiated liposarcoma. The funding will enable basic research, translational studies, and potentially future...
The federal Project Grant award of $1,144,500.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) will support research by the University of Texas MD Anderson Cancer Center to investigate the PRMT3-IGF2BP1 axis-mediated epitranscriptomic reprogramming as a novel therapeutic strategy to overcome immunotherapy resistance in clear cell renal cell carcinoma (CCRCC). The award period runs from September 1, 2025, through August 31, 2028. MD Anderson, a...
This $1,619,723 federal Project Grant award from the Department of Defense's Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides funding to The University of Texas MD Anderson Cancer Center to conduct research targeting novel mediators of breast cancer brain metastasis. The award period runs from April 1, 2024 to March 31, 2027, with the goal of developing new treatments, improving patient care, and advancing scientific understanding in this...
The federal Project Grant award of $735,799.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant is awarded to the University of Texas MD Anderson Cancer Center to support the project "INNOVATING BREAST CANCER RNA THERAPY: MECHANISMS AND PHARMACOGENETIC INHIBITORS". The project aims to conduct advanced biomedical research focused on transforming healthcare for military service members and the broader public,...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides $754,766.00 to The University of Texas M.D. Anderson Cancer Center to investigate the role of microbiota and microbial extracellular vesicles in metastatic dormancy in melanoma. The award period runs from November 1, 2024 to October 31, 2027. The University of Texas M.D. Anderson Cancer Center is a prominent academic medical center with extensive...